Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience

Author： Correale Pierpaolo Cusi Maria Micheli Lucia Nencini Cristina Vecchio Maria Torino Francesco Aquino Angelo Bonmassar Enzo Francini Guido Giorgi Giorgio

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.2, 2006-03, pp. : 99-110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alternating chemo-immunotherapy with temozolomide and interleukin-2 in the treatment of metastatic melanoma

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Anticancer and Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative of LPS for Combined Chemo-immunotherapy

By Roy Aniruddha

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2294-2309

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice

Current Cancer Drug Targets, Vol. 15, Iss. 8, 2015-01 ,pp. : 703-715

Bentham Science Publishers

Access to resources Recommend Favorite

Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results

By Berendsen Sharon Broekman Marike Seute Tatjana Snijders Tom van Es Corine de Vos Filip Regli Luca Robe Pierre

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 9, 2012-09 ,pp. : 1391-1415

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists for Parkinsons Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite